The UCSD CFAR has been in existence since 1994. It serves investigators at UCSD and three participating institutions: the Veterans Medical Research Foundation of the San Diego VA Healthcare System, the Salk Institute and the La Jolla Institute for Allergy and Immunology. The CFAR has significantly enhanced HIV/AIDS activities at the participating institutions and the San Diego Community in general by 1) encouraging young faculty and investigators new to mV/AIDS research through Developmental Grant Awards. 2) Providing expert advice and services in a number of specialized research areas through the CFAR Core Program and 3) fostering research interactions and community wide education through its programs in mentoring, training, education and outreach. The proposed CFAR consists of six cores: Developmental, Molecular Biology, Flow Cytometry (including the Immune Response sub-core), Genomics, Virology and Clinical Investigation. These cores are directly responsible to the Directors and the Executive Committee. Center membership is composed of the 180 faculty spanning 20 Departments in UCSD and the Center's participating institutions. The management of the Center is assisted by the Executive Committee, comprised of six investigators from UCSD and our collaborating institutions who are not directly funded by the CFAR: Bruce Torbett (The Scripps Research Institute), Ned Landau (Infectious Diseases, The Salk Institute), Carl Ware (The La Jolla Institute for Allergy and Immunology, LJIAI), Igor Grant (UCSD, HIV Neurobehavioral Research Center), Allen McCutchan (UCSD, NeuroAIDS), Sam Bozzette (UCSD, Health Services) and Josh Refer (Infectious Diseases, VA Medical Center, VAMC). In addition, our External Advisory Committee meets annually to monitor the scientific direction and growth of the CFAR as well as reviewing and evaluating individual core performance. The Committee offers feedback on our performance in achieving our milestones and aids in the formulation of new directions. The EAC is comprised of a group of internationally renowned AIDS investigators: Ron Desrosiers, David Ho, King Holmes, Eric Hunter, Gary Nabel and Mario Stevenson. Both committees provide us with the opportunity to draw upon and integrate their knowledge and advice, providing objective management decisions and helping guide the Center in new, productive directions. In the past year, several significant improvements have been incorporated into the program. These include a more formal and transparent administrative process of review and decision making, an enhanced Developmental Core, restructuring the CFAR membership into Program Areas to foster more collaboration and interaction and increased efforts in community education and outreach. These improvements are already enhancing the community wide HIV/AIDS activities by our already highly productive and useful CFAR.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036214-13
Application #
7072275
Study Section
Special Emphasis Panel (ZAI1-HSD-A (J1))
Program Officer
Young, Janet M
Project Start
1994-04-01
Project End
2007-07-31
Budget Start
2006-06-01
Budget End
2007-07-31
Support Year
13
Fiscal Year
2006
Total Cost
$1,642,331
Indirect Cost
Name
University of California San Diego
Department
Pathology
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Garfein, Richard S; Liu, Lin; Cuevas-Mota, Jazmine et al. (2018) Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA. Emerg Infect Dis 24:1806-1815
Heldt, Sven; Prattes, Juergen; Eigl, Susanne et al. (2018) Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. J Infect 77:235-241
Jenks, Jeffrey Daniel; Hoenigl, Martin (2018) CD4:CD8 ratio and CD8+ cell count for prognosticating mortality in HIV-infected patients on antiretroviral therapy. J Lab Precis Med 3:
Canan, Chelsea E; Chander, Geetanjali; Monroe, Anne K et al. (2018) High-Risk Prescription Opioid Use Among People Living With HIV. J Acquir Immune Defic Syndr 78:283-290
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
White, Cory H; Beliakova-Bethell, Nadejda; Lada, Steven M et al. (2018) Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment. Front Immunol 9:603
Gianella, Sara; Marconi, Vincent C; Berzins, Baiba et al. (2018) Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy. J Acquir Immune Defic Syndr 79:e112-e114
Innes, Steve; Patel, Kunjal (2018) Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings. Curr Opin HIV AIDS 13:187-195
Morales, Mario; Rafful, Claudia; Gaines, Tommi L et al. (2018) Factors associated with extrajudicial arrest for syringe possession: results of a department-wide survey of municipal police in Tijuana, Mexico. BMC Int Health Hum Rights 18:36
Rhodes, Tim (2018) The becoming of methadone in Kenya: How an intervention's implementation constitutes recovery potential. Soc Sci Med 201:71-79

Showing the most recent 10 out of 921 publications